Eco Animal Health Gp - Share Awards to Executive Directors

ECO Animal Health

11/09/2026 09:11

RNS Number : 4112U
  
Eco Animal Health Group PLC
  
11 September 2026
  
 



11 September 2026









 


ECO Animal Health Group plc


(“ECO” or the “Company”)


 


Share Awards to Executive Directors



ECO Animal Health Group plc (AIM: EAH), a leading global animal health company developing and marketing branded veterinary products to improve livestock productivity and welfare, announces that on 9 September 2026, nominal cost conditional share options were granted under the Company’s Long Term Incentive Plan (“LTIP”) over 404,526 ordinary shares in the Company (representing approximately 0.60 percent of the Company’s issued share capital) to the Executive Directors listed below.


 



Name




Position




Number of Share Awards 




David Hallas




Chief Executive Officer




232,449




Chris Wilks




Chief Financial Officer




172,077



 


These awards under the LTIP are subject to performance conditions being met which have been set by the Company’s Remuneration Committee and relate to Total Shareholder Return (“TSR”) and Research and Development (“R&D”) targets. Subject to the performance conditions being met, awards will vest after the end of a three-year vesting period. Further details on the LTIP can be found in the Company’s 2026 Annual Report which was published on 5 August 2026.


In addition, on 9 September 2026, nominal cost restricted share units (“RSUs”) over 50,566 ordinary shares in the Company (representing approximately 0.07 percent of the Company’s issued share capital) were granted to the two Executive Directors listed below. The RSUs were granted under the LTIP and will vest after the end of a three-year vesting period but are not subject to performance conditions being met. Further details on the RSUs can be found in the Company’s 2026 Annual Report which was published on 5 August 2026.


 



Name




Position




Number of RSUs 




David Hallas




Chief Executive Officer 




29,056




Chris Wilks




Chief Financial Officer 




21,510



 


-Ends-


 


Contacts



 


ECO Animal Health Group plc


David Hallas (Chief Executive Officer)


Christopher Wilks (Chief Financial Officer)


 





020 8447 8899




ICR Healthcare (Financial PR)


Mary-Jane Elliott


Jessica Hodgson


Phillip Marriage


 




020 3709 5700


 




Singer Capital Markets (Nominated Adviser & Joint Broker)


Jen Boorer 


Sara Hale


James Fischer


 


 




020 7496 3000




Panmure Liberum (Joint Broker)


Emma Earl


Will Goode


Mark Rogers


Rupert Dearden


 


 




020 3100 2000 


 


 




Equity Development


Hannah Crowe


Matt Evans




020 7065 2692



 



About ECO Animal Health


 


ECO Animal Health (AIM: EAH) is a leading global animal health company, developing and marketing branded veterinary products that optimise livestock wellbeing and productivity.


 


The Group’s proprietary lead product, Aivlosin® is a market leading antibiotic for the treatment of respiratory and intestinal diseases in pigs and poultry, distributed to over 70 markets through an established commercial platform.


 


ECO Animal Health is also investing in the next generation of animal health products through a self-funded R&D pipeline, with a particular focus on prevention and vaccines. The first product from ECO’s pipeline, ECOVAXXIN® MS, a poultry vaccine targeting Mycoplasma synoviae infection, was commercially launched in the EU in July 2026.


 


Headquartered in the UK, with a global presence, ECO Animal Health employs over 200 people worldwide.


 


View the Group’s website or LinkedIn page for further information. 


PDMR Notification - ECO LTIP Nominal Cost Conditional Share Awards 



1.           




Details of the person discharging managerial responsibilities / person closely associated




a.            




Name




David Hallas


 




2.            




Reason for the notification




a.            




Position/status




Chief Executive Officer


 




b.            




Initial notification


/Amendment


 




Initial notification




3.            




Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a.           




Name




Eco Animal Health Group Plc




b.           




LEI




2138009XN9DJ3YP7OB55




4.            




Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted




a.            




Description of the


Financial instrument, type of instrument


Identification code




Options over ordinary shares of 5p each.


 


GB0032036807 


 




b.            




Nature of the transaction





Award of nominal cost conditional share awards under the Company’s LTIP (“LTIP”)


Award of nominal cost restricted share units (“RSUs”) 





c.            




Price(s) and volume(s)




 



 




 




Price(s)


 




Volume(s)




1.




LTIP




5p




232,449




2.




RSUs




5p




29,056



      




d.            




Aggregated information


Aggregated volume


Price 




 


 


n/a


 




e.            




Date of the transaction




9 September 2026




f.            




Place of the transaction




Off Market


 



 



1.           




Details of the person discharging managerial responsibilities / person closely associated




a.            




Name




Chris Wilks


 




2.            




Reason for the notification




a.            




Position/status




Chief Financial Officer


 




b.            




Initial notification


/Amendment


 




Initial notification




3.            




Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a.           




Name




Eco Animal Health Group Plc




b.           




LEI




2138009XN9DJ3YP7OB55




4.            




Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted




a.            




Description of the


Financial instrument, type of instrument


Identification code




Options over ordinary shares of 5p each.


 


GB0032036807 


 




b.            




Nature of the transaction





Award of nominal cost conditional share awards under the Company’s LTIP (“LTIP”)


Award of nominal cost restricted share units (“RSUs”)





c.            




Price(s) and volume(s)




 


 



 




 




Price(s)


 




Volume(s)




1.




LTIP




5p




172,077




2.




RSUs




5p




21,510



      




d.            




Aggregated information


Aggregated volume


Price 




 


 


n/a


 




e.            




Date of the transaction




9 September 2026




f.            




Place of the transaction




Off Market


 


 



 



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
DSHGIGDCLGBDGLB